Bone Cancer

<p>Epidemiology of Bone Cancer</p> <p>1. Osteoarchaeology: lessons to learn from the past</p> <p>2. Epidemiology of primary bone tumors and economical aspects of bone metastases</p> <p>Models of Bone Cancers and Technical Aspects</p> <p>Animal Models</p> <p>3. Animal models of bone sarcomas</p> <p>4. In vivo models used in studies of bone metastaes</p> <p>5. Zebrafish models for studying bone tumors</p> <p>Mathematic models and machine learning</p> <p>6. Use of machine learning in bone cancers</p> <p>7. Artifical intelligence for bone cancer imaging</p> <p>Preparation of tissue samples: technical aspects</p> <p>8. Technical aspects: how do we best prepare bone samples for proper histological analysis?</p> <p>Bone Microenvironment and Bone Cancer</p> <p>Bone niche</p> <p>9. Bone niche and bone metastases </p> <p>10. Bone: a fertil soil for tumor development</p> <p>11. Osteomimicry: old concepts and new findings </p> <p>Dialog between cancer cells and bone cells</p> <p>12. Role of mesenchymal stem cells in bone cancers, initiation, propagation and metastasis </p> <p>13. Technical approaches for studying the communications between osteocytes and cancer cells</p> <p>14. Osteocytes and bone cancers</p> <p>15. Immune functions of osteoclasts: new insights for bone cancers</p> <p>16. Immune infiltrate in bone sarcomas</p> <p>17. Macrophages and pathophysiology of bone cancers</p> <p>Mediators of cell communications</p> <p>18. Growth factors, cytokines and pediatric malignant primary bones tumors</p> <p>19. The role of NFkB in bone cancer</p> <p>20. TGF-beta and bone cancers: a specific focus </p> <p>21. Extracellular vesicles, tumor growth and metastatic process</p> <p>22. Connexin43 and development of primary bone tumors : osteosarcoma and Ewing’s sarcoma</p> <p>23. The role of endocannabinoid system in bone cancer</p> <p>Metabolism</p> <p>24. Impact of the microenvironment acidosis on bone cancers </p> <p>25. Hypoxic niche and bone cancers</p> <p>26. Metabolism and bone cancers</p> <p>Bone Tumor Heterogeneity, Plasticity and Biomarkers</p> <p>Heterogeneity and plasticity</p> <p>27. EMT process in bone metastasis</p> <p>28. Cancer stem cells and clonal evolution in bone sarcomas</p> <p>29. Dormancy in cancer bone metastasis</p> <p>Biomarkers</p> <p>30. Bone Remodelling Markers and Bone Cancer </p> <p>31. Epigenetic Heterogeneity in Primary Bone Cancers </p> <p>32. miRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors</p> <p>33. MicroRNAs and bone metastasis: how small RNAs regulate secondary tumour formation and progression in the skeleton</p> <p>34. Long-non coding RNA and bone sarcoma</p> <p>35. Liquid biopsy and circulating tumor cells in bone sarcomas: identification of new biomarkers and analysis of the tumor heterogeneity</p> <p>36. Disseminated tumor cells in bone marrow of cancer patients </p> <p>II. PRIMARY BONE TUMORS</p> <p>Biological aspects</p> <p>37. Cytogenetics of bone sarcomas </p> <p>38. Genetic aspects of primary bone tumors</p> <p>39. Markers of bone sarcomas</p> <p>40. Molecular pathology of osteosarcoma</p> <p>41. Genomic and proteomic profiling of osteosarcoma </p> <p>42. Ewing sarcoma family of tumors</p> <p>43. Molecular aspects of Ewing sarcomas </p> <p>44. Osteoclast-rich lesions: a clinical and molecular overview</p> <p>45. Biology of cartilage tumor family</p> <p>Clinical aspects and Perspectives</p> <p>Imaging</p> <p>46. Imaging of bone sarcomas </p> <p>Therapeutic approaches</p> <p>47. Current therapeutic approaches of bone sarcomas</p> <p>48. Surgical approaches of bone sarcomas: Margins and clinical impact </p> <p>49. Apoptosis and drug resistance in malignant bone tumors: impact on the clinical practices </p> <p>50. Chondrosarcoma of Bone: Diagnosis and Therapy </p> <p>51. Radiotherapy and Primary bone tumors</p> <p>52. New therapeutic advances of bone sarcomas</p> <p>III. BONE METASTASES</p> <p>Biological aspects</p> <p>53. The histopathology of skeletal Metastases </p> <p>54. Indentification of new therapeutic targets of bone cancers by proteomic strategies </p> <p>Clinical aspects and Perspectives</p> <p>Imaging</p> <p>55. Interventional radiologic techniques in management of bone tumors </p> <p>56. Diagnosis of bone metastases in urological malignancies – an update</p> <p>Bone pain</p> <p>57. Mechanisms and management of bone cancer pain </p> <p>58. Involvement of sympathic nerves in bone mestastasis</p> <p>59. Pain control with palliative radiotherapy in patients with bone metastases </p> <p>60. Palliative care of bone metastases</p> <p>Therapeutic approaches</p> <p>61. Radiotherapy of bone metastases</p> <p>62. Cellular and molecular actions of bisphosphonates: therapeutic interest in tumor-associated bone diseases</p> <p>63. Bone-Targeted agents and skeletal-related events in breast cancer patients with bone metastases</p> <p>64. Bone metastases – current status of bone-targeted treatments</p> <p>65. Therapies of bone metastases in castration-resistant prostate cancer</p> <p>66. Therapy with bone-targeting radiopharmaceuticals</p> <p>67. Therapeutic approaches of bone metastases associated with breast cancer</p> <p>MYELOMA: A BONE ASSOCIATED DISEASE</p> <p>68. Biological relationship between bone and myeloma cells</p> <p>69. Recent therapeutic approaches in myeloma</p>